Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Clinical trial NCT04305145 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04305145
Sponsor: Massachusetts General Hospital
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma Stage III Melanoma Stage IV Skin Cancer Stage III Skin Cancer Stage IV Drug-Induced Colitis Drug Toxicity Immune-related Adverse Event

Start date: 2020-08-31
Primary completion: 2030-06-30
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.